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ABSTRACT
Out-of-pocket spending is increasingly recognized as an important barrier to accessing health care, particularly in low-
income and middle-income countries (LMICs) where a large portion of health expenditure comes from out-of-pocket
payments. Emerging universal healthcare policies prioritize reduction of poverty impact such as catastrophic and
impoverishing healthcare expenditure. Poverty impact is therefore increasingly evaluated alongside and within economic
evaluations to estimate the impact of speciﬁc health interventions on poverty. However, data collection for these metrics
can be challenging in intervention-based contexts in LMICs because of study design and practical limitations. Using a
set of case studies, this letter identiﬁes methodological challenges in collecting patient cost data in LMIC contexts.
These components are presented in a framework to encourage researchers to consider the implications of differing
approaches in data collection and to report their approach in a standardized and transparent way. © 2016 The Authors.
Health Economics published by John Wiley & Sons Ltd.
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1. INTRODUCTION
As universal access to health care becomes a greater international priority, interest has grown in reducing the level
of ﬁnancial catastrophe and impoverishment caused by health-related expenditure (64th World Health Assembly,
2011). As a result, there is increased recognition that the impact of health interventions on poverty and equity
should be incorporated into economic evaluations (Bill and Melinda Gates Foundation et al., 2014) – particularly
in low-income and middle-income countries (LMICs) where out-of-pocket expenditures make up a large
proportion of total health expenditure (World Health Organization, 2015). This is evidenced by the growing
popularity of ‘extended’ economic evaluations, which incorporate assessments of the potential ﬁnancial risk
protection impact of an intervention or technology (Verguet et al., 2014). In the context of this growing impor-
tance of poverty impact metrics in health planning and decision making, there is need for high-quality data to
estimate the impact of health expenditures on poverty and vulnerability. To date, the majority of research
reporting the poverty impact of health expenditures has drawn on data from large cross-sectional surveys such
as the Living Standards Measurement Survey or World Health Survey. While these datasets facilitate equity
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analyses evaluating the distribution of health impacts or ﬁnancial pooling mechanisms across socioeconomic
status analysis at the national level (Xu et al., 2003; Lu et al., 2009), they cannot be easily used to capture
the impact of a speciﬁc health intervention on poverty and may not always include detail on indirect costs or
income loss, which can be key aspects of the poverty impact of illness.
Collecting this type of data within a smaller-scale study setting can substantially increase the time and
cost of data collection. Many studies therefore avoid collecting data for a poverty impact analysis
altogether. Where poverty impact data are collected as part of intervention evaluations, there are notable
inconsistencies in data collection methods. Systematic reviews of existing patient cost studies in LMICs
highlight a lack of standard approaches across cost ingredients, data sources, sampling methodologies,
and recall periods, even where the same measure of poverty impact is used (Barter et al., 2012; Tanimura
et al., 2014; Kankeu et al., 2013; Alam & Mahal, 2014; McIntyre et al., 2006). This can lead to challenges
in assessing the comparability, quality, and accuracy of results. In part, this heterogeneity may stem from
limited practical guidance or standards on collecting patient-incurred cost data. Reporting guidelines for
economic evaluations largely cover provider perspectives (Drummond & Jefferson, 1996; Husereau et al.,
2013) and are neither updated to reﬂect information necessary for poverty impact metrics nor provide
guidance when constraints in data collection require compromise, such as limiting the sample size or
restricting the length of the questionnaire.
The aim of this letter is to highlight challenges faced in collecting data on patient costs within economic
evaluation platforms in LMICs. We discuss practical issues around collecting patient-incurred cost and house-
hold income data, including comprehensiveness of the survey instrument, timing of interviews, sampling, and
survey administration. To illustrate these issues, we use four case studies from our own research as examples
(Kufa et al., 2014; Foster et al., 2015; Ilboudo et al., 2014; Mﬁnanga et al., 2015) (Table I). Finally, we present
a framework of methodological choices in planning research on poverty impact metrics (Table II) to encourage
researchers to report their approach in a standardized and transparent way and to consider potential implications
of varying approaches in data collection (Figure 1).
2. COMPREHENSIVENESS OF SURVEY DESIGN
There is a rich theoretical literature on the measurement of affordability in health care. The most common
indicators of poverty impact are catastrophic expenditure (deﬁned where health spending exceeds a threshold
percentage of household income) and impoverishing expenditure (deﬁned where health spending pushes a
household below the poverty line) (Wagstaff, 2011; Wagstaff & van Doorslaer, 2014; Wagstaff & Eozenou,
2003). A number of theoretical challenges are associated with estimating the poverty impact of illness, which
are not addressed in detail in this letter, including the appropriate denominator and thresholds for analysis and
how to represent the long-term impact of health spending (Xu et al., 2003; McIntyre et al., 2006; Russell, 1996;
Flores et al., 2008; Niëns et al., 2010; Niëns & Brouwer, 2013; Pal, 2012; Wingﬁeld et al., 2014; Onoka et al.,
2011; Moreno-Serra et al., 2011; Chuma et al., 2006; Sauerborn et al., 1996; Kruk et al., 2009). The data
required are deﬁned by the metric of poverty impact chosen but can include data on direct out-of-pocket
expenditures for health care, any indirect costs of time associated with being ill or accessing care, and any
further economic impact measures such as income loss or loan interest.
The main challenge in survey design is the representation of complex patient experiences within a manage-
able survey length. Survey length is of particular concern when a patient cost questionnaire follows a lengthy
clinical investigation, as it increases the risk of survey fatigue and participation refusal and increases resources
required to conduct the survey. Our four case studies had a range of survey durations; this is largely a function
of the complexity of the patient pathways in question. MERGE and XTEND attempted to cover the overall
costs of a complex illness episode over a range of different providers, whereas ECONPOP covered only a
recent hospitalization and REMSTART covered only the current visit. Survey durations for each study are
detailed in Table I.
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Disaggregation of cost ingredients will also affect survey length, and researchers may need to prioritize cer-
tain aspects to cover in depth. However, it is known that major drivers for patient costs can vary by setting and
across income quintiles (Tanimura et al., 2014; Saksena et al., 2010), making it difﬁcult to pre-suppose any
exclusions or the relative attention placed on each aspect of expenditure or income measured. Surveys should
be adapted to accurately represent the setting of interest, and researchers must be clear about which ingredients
they do include and how ingredients are disaggregated.
Another widely recognized challenge is measurement of permanent income in LMICs, where informal em-
ployment is common and income is often seasonal (Ferguson et al., 2003; Deaton, 1997). Income data are dif-
ﬁcult to collect in a small survey setting; as interviews in an intervention evaluation are conducted individually,
accurate estimation of household income is often impossible. Researchers will need to decide whether personal
income is an appropriate proxy for household income in their study context and be clear about the limita-
tions of such a decision. In the XTEND and MERGE case studies, respondents consistently reported
themselves to be the primary breadwinners in the household; personal income was therefore collected, with
the limitation that these analyses may have underestimated the economic burden on the family as they did
not account for the fact that income is shared amongst household members. On the other hand, within the
ECONPOP sample, respondents were often not the primary breadwinners and often could not estimate
household income. The decision was therefore made to use an assumption of gross domestic product per
capita as a proxy rather than risk breaking the conﬁdentiality of the interview by asking family members.
This decision has implications for the metrics used; in this case, we did not have a ﬁrm understanding of
where households lay in relation to the poverty line at baseline and, therefore, would not have been able
to report on impoverishing expenditures.
Where researchers are unable to collect income directly, asset indices may also be used as a proxy measure of
household socioeconomic position. Information on assets can be simpler to collect than income or consumption
but result in ordinal data (Ferguson et al., 2003). In order to convert an asset index into monetary terms, necessary
for the denominator of threshold metrics such as catastrophic or impoverishing expenditures, these data need to be
mapped to an absolute wealth metric (Hruschka & Hadley, 2015; Howe et al., 2012). This may pose issues if
income diversity in the population of interest is substantially different from that of the national population.
3. TIME FRAME AND RECALL
Deciding on the appropriate timing for the survey may also be difﬁcult in a study where survey timing is based
primarily on outcome measurement. The clinical pathways for some types of illness (for example, TB) can be
long and complex, making recall bias a signiﬁcant concern. This is illustrated in the XTEND survey, where pa-
tients enrolled in the trial could only be interviewed at the end of a 6-month follow-up period. To accommodate
this, an additional sample of those on TB treatment outside the trial enrollees was also surveyed to increase
sample size and allow for shorter recall periods between interviews. When capturing income loss as a result
of illness in the case of complex clinical pathways, researchers will also need to weigh the risks of recall bias
against the anticipated beneﬁt of soliciting information on income before the illness.
There is also the potential for cost truncation in chronic illness or conditions with complications. The long-
term economic impact of illness can be substantial (Ilboudo et al., 2013). This can be captured by following a
cohort along the clinical pathway (as in the XTEND study) or with follow-up surveys conducted later (Ilboudo
et al., 2013). However, it is a particular problem for lifelong treatments such as antiretroviral therapy.
Finally, dissaving or other coping strategies can also be an important reﬂection of the long-term impact of
illness, and where possible, it may be helpful to include questions on coping strategies in the survey. Surveys
may directly ask how households mobilized payment for healthcare services (Flores et al., 2008), or longitudi-
nal surveys may be able to conduct repeated asset surveys, capturing any depletion of assets caused by illness
(Ilboudo et al., 2013). This is only a partial measure of the economic impact of illness on households; however,
it is a useful proxy where income measurement is impossible.
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4. SAMPLE SIZE AND REPRESENTATIVENESS
Sample size considerations are key in the planning stages of a study and will depend on the aims, nature, and scope
of the study, and the degree of precision (conﬁdence interval and margin of error) deemed appropriate (Lwanga &
Lemeshow, 1991). Household surveys generally follow United Nations guidelines of a 5–10% margin of error at
the 95% conﬁdence interval, with further adjustment to account for clustering and non-response (United Nations
Statistical Division, 2008). However, this degree of precision may be difﬁcult to achieve in an intervention-based
context, and researchers need to be pragmatic. Some trade-off in error margin will likely need to be made in the
interests of practicality of the survey; this is especially true for outcomes that are particularly rare in the population
of interest, as illustrated in Table I. This decision should also be taken within the context of the larger uncertainty
associated with the survey – for example, spending more time in the interview to avoid recall bias may produce
more reliable results than spending additional time interviewing a great many more patients.
In each of our case studies, the sampling for out-of-pocket expenditures was restricted to a subsample of
participants because of practical considerations of the study; for MERGE, XTEND, and ECONPOP, a subsam-
ple of the study population was taken, while in REMSTART, the number of follow-up visits was limited.
Table I shows the sample size for each case study and the ideal sample sizes necessary for various speciﬁcations
of relative precision to estimate catastrophic expenditure.
Sampling considerations pose particular issues for the estimation of impoverishing expenditures when most
patients are already below the poverty line – for example, where targeting those already in poverty may be a
desired feature of interventions or where investigating diseases such as HIV and TB, which disproportionately
affect those below the poverty line (Bates et al., 2004). When this is the case, impoverishment becomes
infrequent, making power to detect the true proportion of impoverishment very low; a different metric of
poverty impact should be used in these cases. All three case studies estimating income had a large proportion
of poor patients: 64% of XTEND patients, 45% of MERGE patients, and 70% of REMSTART patients had a
pre-diagnosis income below the national poverty lines (Chibuye, 2014; Statistics South Africa, 2014; OECD,
2013; Laokri et al., 2013).
5. DATA SOURCES AND SURVEY ADMINISTRATION
Finally, researchers will need to identify data sources and plan administration of the survey. Researchers from
the Database of Instruments for Resource Use Measurement team working in a high-income country setting
(Ridyard et al., 2015) propose a taxonomy for methods of resource use measurement including the following:
the source of data, who completes the resource use measurement, how it is administered, how it is recorded, and
the medium of recording. Work in LMICs requires some additional consideration, as described subsequently.
Cost diaries are considered to be the gold standard in patient cost collection (Wiseman et al., 2005; Goossens
et al., 2000), but they can be time and cost intensive for researchers, especially where there is high illiteracy; patient
recall is more common in low-income settings (Beegle et al., 2012). This can be supplemented with geographic
information system or other mapping data to facilitate estimation and veriﬁcation of travel costs where patients
are unable to estimate distances (Siedner et al., 2013), and retrospective records review can also combat recall bias
in the case of frequent health facility visits (Das et al., 2012). Information on resource use can also bematched with
price data tominimize recall bias; however, in LMIC, there is muchwider variation in price, andmarket prices may
not accurately reﬂect the economic value of resources (Hutton & Baltussen, 2005).
There may also be a distinction in survey quality depending on the interviewer and where the interview takes
place. Independent research assistants may be preferable to nurses if the subject material is sensitive. Individual
income and spending can be sensitive, and patients may be inclined to under-report or over-report income if the
purpose of the interview is not well understood (Morris et al., 2000). Using trained interviewers who under-
stand the principles and rationale for collecting patient costs also substantially affects the quality of the data;
for example, the MERGE study initially experienced poor data quality, which improved after retraining
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interviewers. Similarly, the location of the interview will affect data quality; perceived privacy will impact pa-
tient recall and willingness to disclose details on income and spending.
Finally, the medium of recording will require particular consideration in LMICs. Electronic or telephone
surveys may facilitate survey completion (Walther et al., 2011) but will require some further training of inter-
viewers in data entry and security, and planning for power and connectivity issues in ﬁeldwork.
6. DISCUSSION
Using the aforementioned four case studies, we have highlighted important considerations in measuring patient
costs and income in order to estimate the impact of illness on economic vulnerability in intervention-based
contexts in LMICs.
Poverty impact metrics are currently data hungry and are therefore often excluded from study surveys be-
cause of time and budgetary constraints in a research study. Going forward in these settings, economists ﬁrst
and foremost have a responsibility to communicate data requirements in the study design phase and advocate
for the collection of patient cost data as an essential part of the economic evaluation. Additional information on
patient costs and the poverty impact of health spending is more costly to collect, but these forms of analysis are
increasingly important to policy makers and program planners and therefore have a high value of information.
Inevitably, some degree of variation in methods will occur across studies where context and data availability
vary. Economists therefore also must communicate with each other where different approaches are possible or
where compromise as to the gold standard of data collection may be managed. Robust reporting of data collection
methods can help other researchers understand and interpret ﬁndings and facilitate standardization of methods. Our
recommendations for reporting data collection methods for patient costs are summarized in Table II.
Finally, it may be possible to minimize the additional cost of collecting patient cost and poverty impact data,
through restricting data needs and clarifying where alternative methods are acceptable. Several alternative methodo-
logical approaches are available, and researchers must weigh limitations of potential alternatives in their own setting.
Some potential advantages and limitations of various methodological approaches are described in Figure 1. We ad-
vocate for further methodological work to investigate the means to minimize the impact of cost ingredient aggrega-
tion, cost truncation, and other forms of compromise when planning poverty impact studies in LMICs, and to
investigate the external validity of results that parallel effect estimates particularly in clinical trials.
Table II. Framework for planning/reporting data collection
Study planning component Items for consideration
Comprehensiveness of survey
design
• Which OOP expenditures are included?
• What is the level of disaggregation in cost ingredients and how long is the survey?
• Are any context-speciﬁc variables included?
• How is income measured, and whose income is collected (i.e., personal or household income)?
Time frame and recall • What is the recall period for the survey? Is it appropriate to capture all economic outcomes?
• What is the complexity of the disease pathway? Is there resulting potential for recall bias?
• Is there potential for cost truncation in the context of chronic disease and/or future complications?
• Are coping strategies used to estimate the long-term economic impact of health spending?
• What is the recall period for income measurement (i.e., current vs. pre-diagnosis)?
Sample size and
representativeness
• What is the conﬁdence interval and margin of error deemed acceptable?
• If estimating impoverishing expenditures, what is the distribution of pre-diagnosis income relative
to the poverty line?
• Are any adjustments to sample size required to account for clustering or non-response?
Data sources and survey
administration
• Is a cost diary or recall used to capture expenditures?
• Are data supplemented with any additional data sources, such as retrospective records review or GIS data?
• Where is the interview conducted and by whom?
• What is the medium of collecting and recording data (i.e., electronic, paper, or telephone surveys)?
GIS, geographic information system.
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Figure 1. Potential advantages and limitations of alternative approaches in data collection
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This supplement conﬁrms the increasing implementation and sophistication of economic evaluation in LMICs
(Vassall et al., 2016; Pitt et al., 2016). Going forward in these settings, evaluations need to tackle policy concerns
around equity and poverty. Researchers should be challenged to address fundamental data gaps for measuring the
impact of illness on economic vulnerability through stronger reporting of methods and further methodological work.
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